Study identifier:D589LL00001
ClinicalTrials.gov identifier:NCT01711840
EudraCT identifier:N/A
CTIS identifier:N/A
Symbicort Turbuhaler 30/60 Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms
Bronchial Asthma
-
No
-
All
2409
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jul 2016 by AstraZeneca
AstraZeneca
-
The purpose of the investigation is to confirm the safety of patients receiving Symbicort Turbuhaler as maintenance and reliever therapy ( Symbicort SMART) under the post-marketing actual use.
Symbicort Turbuhaler 30/60 Clinical Experience Investigation for treatment with Symbicort as maintenance therapy and as needed in response to symptoms
Location
Location
Gunma, D589LL00001, Japan
Location
Gunma, D589LL00001, Japan
Location
Gunma, D589LL00001, Japan
Location
Saitama, D589LL00001, Japan
Location
Saitama, D589LL00001, Japan
Location
Chiba, D589LL00001, Japan
Location
Chiba, D589LL00001, Japan
Location
Chiba, D589LL00001, Japan
Arms | Assigned Interventions |
---|---|
Symbicort | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.